Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

Mise à jour : Il y a 4 ans
Référence : NCT00172367

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma. Secondary Objective: To evaluate the general safety and tolerability of oral lycopene 30 mg per day for 12 weeks in uremic patients.


Critère d'inclusion

  • Carcinoma, Transitional Cell

Liens